



## FEP Medical Policy Manual

### FEP 2.04.07 Urinary Biomarkers for Cancer Screening, Diagnosis, and Surveillance

Annual Effective Policy Date: April 1, 2024

Original Policy Date: December 2011

Related Policies:

None

## Urinary Biomarkers for Cancer Screening, Diagnosis, and Surveillance

### Description

#### Description

The diagnosis of bladder cancer is generally made by cystoscopy and biopsy. Bladder cancer has a very high frequency of recurrence and therefore follow-up cystoscopy, along with urine cytology, is done periodically to identify recurrence early. Urine biomarkers that might be used to supplement or supplant these tests have been actively investigated. Urinary biomarkers have also been suggested to have utility in identifying colonic polyps.

#### OBJECTIVE

The objective of this evidence review is to evaluate whether the diagnostic use of urinary tumor markers improves the net health outcome for individuals with suspected or history of bladder cancer or for the screening of asymptomatic individuals for bladder cancer or colonic polyps.

#### POLICY STATEMENT

The use of urinary tumor markers is considered **not medically necessary** in the screening, diagnosis of, and monitoring for bladder cancer, or screening for precancerous colonic polyps.

## POLICY GUIDELINES

None

## BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

## FDA REGULATORY STATUS

Table 1 lists urinary tumor marker tests approved or cleared for marketing by the FDA. The FDA approved or cleared tests are indicated as adjuncts to standard procedures for use in the initial diagnosis of bladder cancer, surveillance of bladder cancer patients, or identification of colonic polyps.

**Table 1. FDA Approved or Cleared Urinary Tumor Marker Tests**

Test	Manufacturer	Type	Detection	Indication
BTA <i>stat</i>	Polymedco	Point of care immunoassay	Human complement factor H-related protein	Qualitative detection of bladder tumor-associated antigen in the urine of persons diagnosed with bladder cancer
BTA TRAK	Polymedco	Reference laboratory immunoassay	Human complement factor H-related protein	Quantitative detection of bladder tumor-associated antigen in the urine of persons diagnosed with bladder cancer
Alere NMP22	Alere	Immunoassay	NMP22 protein	in vitro quantitative determination of the nuclear mitotic apparatus protein (NuMA) in stabilized voided urine. Used as adjunct to cystoscopy
BladderChek	Alere	Point of care immunoassay	NMP22 protein	Adjunct to cystoscopy in patients at risk for bladder cancer
UroVysion	Abbott Molecular	FISH <sup>a</sup>	Cell-based chromosomal abnormalities	Aid in the initial diagnosis of bladder cancer (P030052) and monitoring patients with previously diagnosed bladder cancer (K033982)
Bladder EpiCheck	Nucleix	RT-PCR	DNA methylation biomarkers	Monitoring for tumor recurrence in conjunction with cystoscopy in patients with previously diagnosed NMIBC

FDA: U.S. Food and Drug Administration; FISH: fluorescence in situ hybridization; NMIBC: non-muscle invasive bladder cancer; NMP: nuclear matrix protein; RT-PCR: real-time polymerase chain reaction.

<sup>a</sup> FISH is a molecular cytogenetic technology that can be used with either DNA or RNA probes to detect chromosomal abnormalities. DNA FISH probe technology involves the creation of short sequences of fluorescently labeled, single-strand DNA probes that match target sequences. The probes bind to complementary strands of DNA, allowing for identification of the location of the chromosomes targeted.

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Urine-based tests are available under the auspices of CLIA. Laboratories that offer laboratory-developed tests must be licensed by CLIA for high-complexity testing. To date, the FDA has chosen not to require any regulatory review of these tests. Laboratory-developed tests include:

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

- Cxbladder Monitor (Pacific Edge) measures the expression of 5 genes (*MDK*, *HOXA13*, *CDC2*, *IGFBP5*, *CXCR2*). Pacific Edge also has Cxbladder Detect and Cxbladder Triage tests.
- Xpert Bladder Cancer Monitor (Cepheid) measures mRNA (*ABL1*, *CRH*, *IGF2*, *UPK1B*, *ANXA10*) in voided urine by reverse transcription-polymerase chain reaction (RT-PCR).
- PolypDx™ (Metabolomic Technologies) is a urine metabolite assay that uses liquid chromatography-mass spectrometry. An algorithm compares urine metabolite concentrations to determine the likelihood of colonic adenomatous polyps.

## RATIONALE

### Summary of Evidence

For individuals who have signs and/or symptoms of bladder cancer who receive urinary tumor marker tests in addition to cystoscopy, the evidence includes a number of diagnostic accuracy studies and meta-analyses of these studies. Relevant outcomes are overall survival (OS), disease-specific survival, test accuracy and validity, and resource utilization. A meta-analysis of diagnostic accuracy studies determined that urinary tumor marker tests have a sensitivity ranging from 47% to 82% and specificity ranging from 53% to 95%. This analysis found that combining urinary tumor markers with cytology improves diagnostic accuracy, but about 10% of cancers would still be missed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have a history of bladder cancer who receive urinary tumor marker tests in addition to cystoscopy, the evidence includes a number of diagnostic accuracy studies and meta-analyses, as well as a decision curve analysis and a retrospective study examining the clinical utility of urinary tumor marker tests. Relevant outcomes are OS, disease-specific survival, test accuracy and validity, and resource utilization. The diagnostic accuracy studies found that urinary tumor marker tests have pooled sensitivity ranging from 52% to 84% and pooled specificity ranging from 71% to 91%. The decision analysis found only a small clinical benefit for use of a urinary tumor marker test and the retrospective study found that a urinary tumor marker test was not significantly associated with findings of the subsequent surveillance cystoscopy. No studies using the preferred trial design to evaluate clinical utility were identified; ie, controlled studies prospectively evaluating health outcomes in patients managed with and without the use of urinary tests or prospective studies comparing different cystoscopy protocols used in conjunction with urinary tumor markers. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are asymptomatic and at a population-level risk of bladder cancer who receive urinary tumor marker tests, the evidence includes a systematic review and several uncontrolled prospective and retrospective studies. Relevant outcomes are OS, disease-specific survival, and test accuracy and validity. A 2010 systematic review (conducted for the U.S. Preventive Services Task Force) did not identify any randomized controlled trials, the preferred trial design to evaluate the impact of population-based screening and found only 1 prospective study that the Task Force rated as poor quality. A more recent retrospective study, assessing a population-based screening program in the Netherlands, reported low diagnostic yield. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are asymptomatic and at a population-level risk of colon cancer who receive urinary tests for precancerous polyps, the evidence includes a validation study. Relevant outcomes are OS, disease-specific survival, and test accuracy and validity. The clinical data supporting a urine metabolite assay for adenomatous polyps includes a report of a training and validation set published in 2017. Current evidence does not support the diagnostic accuracy of urinary tumor markers to screen asymptomatic individuals for precancerous polyps. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## SUPPLEMENTAL INFORMATION

### Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in "Supplemental Information" if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

## National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN; v3.2023 ) bladder cancer guidelines include consideration for urinary urothelial tumor markers every 3 months along with urine cytology for the first 2 years of follow-up for high-risk patients with non-muscle-invasive bladder cancer (category 2B recommendation).<sup>17</sup> The guidelines include the following statement: "Many of these tests have a better sensitivity for detecting bladder cancer than urinary cytology, but specificity is lower. Considering this, evaluation of urinary urothelial tumors may be considered during surveillance of high-risk non-muscle-invasive bladder cancer. However, it remains unclear whether these tests offer additional useful information for detection and management of non-muscle-invasive bladder tumors."

The NCCN colorectal cancer screening guidelines (v3.2023 ) do not mention use of urinary tumor markers for detection of colon cancer in asymptomatic individuals at population-level risk of colon cancer.<sup>17</sup> Colonoscopy or fecal testing are recommended for screening purposes in these individuals.

## American Urological Association and Society of Urologic Oncology

The guidelines from the American Urological Association and Society of Urologic Oncology (2016; amended 2020) addressed the diagnosis and treatment of non-muscle-invasive bladder cancer, based on a systematic review completed by the Agency for Health Care Research and Quality and through additional supplementation that further addressed key questions and more recently published literature.<sup>18</sup> Table 2 summarizes statements on the use of urine markers after the diagnosis of bladder cancer.

**Table 2. Guidelines for Urine Tumor Markers After the Diagnosis of Bladder Cancer**

Guidance Statement	SOR	LOE
"In surveillance of NMIBC, a clinician should not use urinary biomarkers in place of cystoscopic evaluation."	Strong	B
"In a patient with a history of low-risk cancer and a normal cystoscopy, a clinician should not routinely use a urinary biomarker or cytology during surveillance."		Expert opinion
"In a patient with NMIBC, a clinician may use biomarkers to assess response to intravesical BCG (UroVysion FISH) and adjudicate equivocal cytology (UroVysion FISH and ImmunoCyt™)."		Expert opinion

BCG: bacillus Calmette-Gurin; FISH: fluorescence in situ hybridization; LOE: level of evidence; NMIBC: non-muscle-invasive bladder cancer; SOR: strength of recommendation.

## American Urological Association/Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction

In 2020, the American Urological Association/Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction published a guideline on the diagnosis, evaluation, and follow-up of microhematuria.<sup>19</sup> This guideline recommended the following with regard to urinary markers:

- Clinicians should not use urine cytology or urine-based tumor markers in the initial evaluation of patients with microhematuria. [Strong recommendation; Evidence level: Grade C]
- Clinicians may obtain urine cytology for patients with persistent microhematuria after a negative workup who have irritative voiding symptoms or risk factors for carcinoma in situ. [Expert opinion]

## U.S. Preventive Services Task Force Recommendations

The **U.S. Preventive Services Task Force** (USPSTF; 2011) concluded that there was insufficient evidence to assess the benefits and harms of screening for bladder cancer in asymptomatic adults.<sup>20</sup> The recommendation was based on insufficient evidence (grade I). In November 2021 , a literature surveillance report was published that scanned for relevant literature in PubMed and PubMed databases and the Cochrane library from 2009 to present.<sup>21</sup> The researchers found no relevant studies on the impact of screening for bladder cancer on morbidity and mortality, outcomes of

treatment of screen-detected bladder cancer, or harms of screening for or treatment of screen-detected bladder cancer. Additionally, no studies compared the benefits or harms of treatment of screen-detected bladder cancer with no treatment.

The USPSTF (2021) recommendation for screening for colorectal cancer "does not include serum tests, urine tests, or capsule endoscopy for colorectal cancer screening because of the limited available evidence on these tests and because other effective tests are available."<sup>22</sup>,

## Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

## REFERENCES

1. Comprat E, Amin MB, Cathomas R, et al. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. *Lancet*. Nov 12 2022; 400(10364): 1712-1721. PMID 36174585
2. Chou R, Buckley D, Fu R, et al. Emerging Approaches to Diagnosis and Treatment of NonMuscle-Invasive Bladder Cancer (Comparative Effectiveness Review No. 153). Rockville, MD: Agency for Healthcare Research and Quality; 2015
3. Fernandez CA, Millholland JM, Zwarthoff EC, et al. A noninvasive multi-analyte diagnostic assay: combining protein and DNA markers to stratify bladder cancer patients. *Res Rep Urol*. 2012; 4: 17-26. PMID 24199176
4. Zuiverloon TC, van der Aa MN, van der Kwast TH, et al. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. *Clin Cancer Res*. Jun 01 2010; 16(11): 3011-8. PMID 20404005
5. Zuiverloon TC, Beukers W, van der Keur KA, et al. Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project. *J Urol*. May 2013; 189(5): 1945-51. PMID 23201384
6. D'Elia C, Folchini DM, Mian C, et al. Diagnostic value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer: an update. *Ther Adv Urol*. 2021; 13: 1756287221997183. PMID 33747133
7. Pichler R, Fritz J, Tulchiner G, et al. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance. *BJU Int*. Jan 2018; 121(1): 29-37. PMID 28941000
8. US Food and Drug Administration. 510(k) Summary for Bladder EpiCheck Test (K203245). May 2023; [https://www.accessdata.fda.gov/cdrh\\_docs/pdf20/K203245.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf20/K203245.pdf). Accessed October 22, 2023
9. Grocela JA, McDougal WS. Utility of nuclear matrix protein (NMP22) in the detection of recurrent bladder cancer. *Urol Clin North Am*. Feb 2000; 27(1): 47-51, viii. PMID 10696244
10. Shariat SF, Savage C, Chromecki TF, et al. Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis. *Cancer*. Jul 01 2011; 117(13): 2892-7. PMID 21692050
11. Kim PH, Sukhu R, Cordon BH, et al. Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy. *BJU Int*. Sep 2014; 114(3): 354-9. PMID 24128299
12. Chou R, Dana T. Screening adults for bladder cancer: a review of the evidence for the U.S. preventive services task force. *Ann Intern Med*. Oct 05 2010; 153(7): 461-8. PMID 20921545
13. Bangma CH, Loeb S, Busstra M, et al. Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers. *Eur Urol*. Jul 2013; 64(1): 41-7. PMID 23478169
14. Lotan Y, Elias K, Svatek RS, et al. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. *J Urol*. Jul 2009; 182(1): 52-7; discussion 58. PMID 19450825
15. US Preventative Services Task Force. Colorectal cancer screening. 2021; <https://www.uspreventiveservicestaskforce.org/uspstf/document/RecommendationStatementFinal/colorectal-cancer-screening>. Accessed October 22, 2023.
16. Deng L, Chang D, Foshaug RR, et al. Development and Validation of a High-Throughput Mass Spectrometry Based Urine Metabolomic Test for the Detection of Colonic Adenomatous Polyps. *Metabolites*. Jun 22 2017; 7(3). PMID 28640228
17. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Colorectal Cancer Screening. Version 3.2023. [https://www.nccn.org/professionals/physician\\_gls/pdf/colorectal\\_screening.pdf](https://www.nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdf). Accessed October 21, 2023.
18. Chang SS, Boorjian SA, Chou R, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. *J Urol*. Oct 2016; 196(4): 1021-9. PMID 27317986
19. Barocas DA, Boorjian SA, Alvarez RD, et al. Microhematuria: AUA/SUFU Guideline. *J Urol*. Oct 2020; 204(4): 778-786. PMID 32698717
20. U.S. Preventive Services Task Force (USPSTF). Bladder cancer in adults: Screening. Recommendation statement. 2011; <https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/bladder-cancer-in-adults-screening>. Accessed October 22, 2023.
21. U.S. Preventive Services Task Force Literature Surveillance Report Bladder Cancer in Adults: Screening. 2021. <https://www.uspreventiveservicestaskforce.org/uspstf/document/literature-surveillance-report/bladder-cancer-in-adults-screening>. Accessed October 22, 2023.
22. US Preventative Services Task Force. Colorectal cancer screening. 2021; <https://www.uspreventiveservicestaskforce.org/uspstf/document/RecommendationStatementFinal/colorectal-cancer-screening>. Accessed October 22, 2023.

## POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
December 2011	New policy	
June 2013	Replace policy	Policy updated with literature review, policy statement unchanged.
June 2014	Replace policy	Policy updated with literature review. Policy statement unchanged. References 4, 23, & 25 added; others renumbered or removed.
June 2015	Replace policy	Policy updated with literature review through February 2015. Policy statement unchanged. References 3, 5, and 15 added.
October 2018	Replace policy	Policy updated with literature review through April 9, 2018; references 1, 8, 11-12, and 20 added; some references removed. Urinary bladder cancer tumor markers as an adjunct in the monitoring of bladder cancer changed from "medically necessary, to "not medically necessary,. Title changed to "Urinary Biomarkers for Cancer Diagnosis and Surveillance.,
March 2019	Replace policy	Policy updated with literature review through October 4, 2018; references 5-6 added. Policy statement unchanged.
March 2020	Replace policy	Policy updated with literature review through October 30, 2019; no references added. Title revised to remove "screening" as policy does not address due to screening benefit language. Policy statement unchanged.
March 2021	Replace policy	Policy updated with literature review through October 30, 2020; references added. Policy statement unchanged.
March 2022	Replace policy	Policy updated with literature review through October 26, 2021; references added. Policy statement unchanged.
March 2023	Replace policy	Policy updated with literature review through October 18, 2022; references added. Policy statements unchanged.
March 2024	Replace policy	Policy updated with literature review through October 22, 2023; references added. Policy statements unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.